Cetuximab, an Epidermal growth factor receptor monoclonal antibody conjugated with IRDye800, successfully localizes to tumors in orthotopic animal models of GBM under NIR image system.[19,36] The first-in-human study was published in 2018, which showed the potential to maximize the extent of primary tumor resection and to identify residual tumors.[20] However, its application requires additional clinical studies. This evidence concerns the gene EGFR and glioblastoma.